Filing Details

Accession Number:
0001104659-15-016811
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-03-04 20:13:47
Reporting Period:
2015-03-01
Filing Date:
2015-03-04
Accepted Time:
2015-03-04 20:13:47
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1100412 Array Biopharma Inc ARRY Pharmaceutical Preparations (2834) 841460811
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1454001 Ron Squarer C/O Array Biopharma Inc.
3200 Walnut Street
Boulder CO 80301
Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-03-01 77,881 $7.96 77,881 No 4 M Direct
Common Stock Disposition 2015-03-01 24,954 $7.96 52,927 No 4 F Direct
Common Stock Disposition 2015-03-02 40,000 $8.25 12,927 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 F Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2015-03-01 77,881 $0.00 77,881 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
77,881 2018-08-18 No 4 M Direct
Footnotes
  1. Shares issued upon settlement of Restricted Stock Units ("RSUs") granted by the Issuer on August 18, 2014 as a result of the vesting of one half of such RSU's.
  2. Represents shares withheld to satisfy tax withholding obligations of the reporting person.
  3. The price reflects the weighted average price for the 40,000 shares which were sold in the range of $8.22 - $8.28. Full information about the number of shares sold at each price is available upon request.
  4. RSU's were awarded to the reporting person for no additional cash consideration and represent a contingent right to receive one share of Array BioPharma Inc. common stock. RSU's representing 32,069 shares of common stock vested on March 1, 2015 and 32,069 shares remain unvested and subject to achievement of a second milestone relating to the return of rights to binimetinib to the issuer on or prior to the fourth anniversary of the grant date, in each case subject to continued service with the Company as of each vesting date.